Cluster analysis and clinical asthma phenotypes
Rationale: Heterogeneity in asthma expression is multidimensional, including variability in
clinical, physiologic, and pathologic parameters. Classification requires consideration of …
clinical, physiologic, and pathologic parameters. Classification requires consideration of …
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics
…, P Montuschi, M Sanak, T Sandstrom, DE Shaw… - Journal of Allergy and …, 2017 - Elsevier
Background Asthma is a heterogeneous disease in which there is a differential response to
asthma treatments. This heterogeneity needs to be evaluated so that a personalized …
asthma treatments. This heterogeneity needs to be evaluated so that a personalized …
“T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin
Type-2 (T2) immune responses in airway epithelial cells (AECs) classifies mild–moderate
asthma into a T2-high phenotype. We examined whether currently available clinical …
asthma into a T2-high phenotype. We examined whether currently available clinical …
[HTML][HTML] Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre …
…, G Jones, P McCourt, M Nunez, DE Shaw… - The Lancet …, 2021 - thelancet.com
Background Asthma treatment guidelines recommend increasing corticosteroid dose to
control symptoms and reduce exacerbations. This approach is potentially flawed because …
control symptoms and reduce exacerbations. This approach is potentially flawed because …
Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma
…, N Krug, J Musial, K Sun, JH Riley, DE Shaw… - Journal of Allergy and …, 2019 - Elsevier
Background Severe asthma is a heterogeneous condition, as shown by independent cluster
analyses based on demographic, clinical, and inflammatory characteristics. A next step is to …
analyses based on demographic, clinical, and inflammatory characteristics. A next step is to …
Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis
…, N Krug, T Sandstrom, DE Shaw… - European respiratory …, 2018 - Eur Respiratory Soc
Severe asthma patients with a significant smoking history have airflow obstruction with
reported neutrophilia. We hypothesise that multi-omic analysis will enable the definition of …
reported neutrophilia. We hypothesise that multi-omic analysis will enable the definition of …
Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study
…, DR Webb, G Housley, D Shaw… - The lancet Diabetes & …, 2016 - thelancet.com
Background Studies in the USA and Canada have reported increasing or stable rates of
hospital admissions for hypoglycaemia. Some data from small studies are available for other …
hospital admissions for hypoglycaemia. Some data from small studies are available for other …
Two heads are better than one? How to effectively use two interviewers to elicit cues to deception
S Mann, A Vrij, DJ Shaw, S Leal… - Legal and …, 2013 - Wiley Online Library
Background. We examined the effect of a second interviewer's demeanour on cues to
deception. We predicted that a supportive demeanour would be the most beneficial for eliciting …
deception. We predicted that a supportive demeanour would be the most beneficial for eliciting …
[HTML][HTML] Extra-cellular matrix proteins induce matrix metalloproteinase-1 (MMP-1) activity and increase airway smooth muscle contraction in asthma
…, D Clements, A Dongre, TW Harrison, D Shaw… - PloS one, 2014 - journals.plos.org
Airway remodelling describes the histopathological changes leading to fixed airway
obstruction in patients with asthma and includes extra-cellular matrix (ECM) deposition. Matrix …
obstruction in patients with asthma and includes extra-cellular matrix (ECM) deposition. Matrix …
Clinical and transcriptomic features of persistent exacerbation‐prone severe asthma in U‐BIOPRED cohort
…, N Krug, T Sandstrom, DE Shaw… - Clinical and …, 2022 - Wiley Online Library
… Dr Shaw has received speaker fees from Chiesi and Astra Zeneca and advisory board fees
from Adherium, Nuvoair, Astra Zeneca and Chiesi. Dr Loza is employed by and own stock in …
from Adherium, Nuvoair, Astra Zeneca and Chiesi. Dr Loza is employed by and own stock in …